Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California
'We are pleased to expand access to Nociscan in our Santa Monica location,' said Bradley Jabour, MD, founder of MICSC. 'MICSC has a proud heritage of adoption of new and novel solutions that add value to our patients and referring physician customers. Nociscan has been an integral part of our Beverly Hills service offering and by adding it in Santa Monica we are expanding our services while replicating the benefits to patients and physicians currently provided in Beverly Hills. Physicians treating low back pain are constantly striving for more and better information when diagnosing and treating patients. Nociscan is helping physicians who treat low back pain and we are pleased to offer Nociscan at both our Los Angeles locations.'
In November 2024, Dr. Jabour was highlighted in an article about Nociscan in the Radiological Society of North America edition of MAGNETOM Flash, a peer-to-peer magazine published by Siemens Healthineers. The article features two physician-user perspectives on Nociscan, one from a spine surgeon and the other from Dr. Jabour's point of view as a radiologist and imaging center owner.
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Los Angeles is the most populous city in California, with an estimated population exceeding 3.8M people, and the second-most populous city in the United States, second only to New York City. Both Los Angeles and New York City are strategically important markets for Aclarion.
Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain.
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
All organizations cited and/or quotes from individuals not part of Aclarion have reviewed and approved the contents herein.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ('MRS'), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as 'anticipates,' 'believes' and 'expects' or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. SmithPCG Advisory, Inc.ksmith@pcgadvisory.com
Media Contacts:
Jennie KimSPRIG Consultingjennie@sprigconsulting.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst
Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly's recent setback and expand treatment options beyond injections. The study, which began in January 2025, will assess the safety, tolerability, pharmacokinetics and weight-loss efficacy of once-daily oral dosing over a 13-week period. VK2375 is being developed in oral and subcutaneous formulations. The target population consists of adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid study's primary endpoint is the percent change in body weight from baseline after 13 weeks of treatment. Secondary and exploratory endpoints will evaluate additional safety and efficacy measures. Viking expects to release results in the second half of 2025, with William Blair projecting an August readout. Analyst Andy Hsieh wrote Tuesday, 'Our base-case expectation is to replicate the 4-week Phase I results, translating to a placebo-adjusted weight loss of slightly under 7% for the highest doses.' Hsieh highlighted the advantage of using the same active ingredient across oral and injectable formats, allowing patients to switch between the two without increasing the risk of new side effects. William Blair reiterated its Outperform rating on Viking shares. Given the underwhelming weight loss magnitude from Eli Lilly and Co.'s (NYSE:LLY) Phase 3 ATTAIN-1 trial of orforglipron, coupled with potential uncertainties associated with the persistent rate of adverse events, the analyst believes the setback creates a clinical void for smaller competitors to fill. 'We expect Viking to rise to the occasion and demonstrate the potential of the oral tablet formulation of VK2735 as a competitive option in the maintenance setting. We therefore would be buyers before the Phase II VENTURE-oral readout,' William Blair wrote in an investor note on Tuesday. In June, Viking Therapeutics initiated the VANQUISH Phase 3 clinical program for subcutaneous VK2735. In 2024, Viking announced topline results from the Phase 2 VENTURE study of subcutaneous VK2735 in obesity. Patients receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7%, and statistically significant reductions in mean body weight relative to placebo, ranging up to 13.1%. Price Action: VKTX stock is trading higher by 2.38% to $40.81 at last check Wednesday. Read Next:Image via Shutterstock Latest Ratings for VKTX Date Firm Action From To Feb 2022 Raymond James Maintains Outperform Jul 2021 Raymond James Maintains Outperform May 2021 Raymond James Downgrades Strong Buy Outperform View More Analyst Ratings for VKTX View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
JUST PUBLISHED: Audrey Kuhn's Poetic Journey Through Love, Loss, and Resilience Amid Alzheimer's and Pandemic Struggles
Audrey Kuhn's poignant reflections on love, loss, and faith, published by Palmetto Publishing, illuminate resilience amid Alzheimer's and caregiving challenges. God's Voice Through the Despair Charleston, SC, Aug. 13, 2025 (GLOBE NEWSWIRE) -- God's Voice Through the Despair, authored by Audrey L. Kuhn, unveils a deeply personal journey through love, loss, and faith amid the trials of Alzheimer's, a global pandemic, and the challenges of caregiving. Audrey's narrative captures her experience as a devoted caregiver for her husband, who faces the devastating effects of Alzheimer's. Over 260 days of separation due to pandemic restrictions test her resilience, forcing her to confront the emotional weight of watching her beloved partner gradually fade away. In her darkest moments, Audrey finds solace through poetry, beginning with the poignant piece 'Little Tears,' which ignites a cascade of reflections that articulate her innermost feelings of sorrow and hope. Audrey L. Kuhn's verses explore intricate themes of love, loss, and the search for meaning amid chaos. Each poem serves as a testament to her strength, revealing the beauty of nature and the spiritual lessons learned through adversity. Her words resonate with the struggles of caregiving, encapsulating vulnerability and the courage needed to face each day. As she navigates the complexities of her husband's illness, Audrey's unwavering faith becomes her guiding light, offering comfort not only to herself but also to others grappling with similar challenges. God's Voice Through the Despair culminates in a heartfelt farewell, a final expression of love that transcends the pain of separation. This collection stands as a beacon of hope for anyone enduring the trials of caregiving, loss, and the quest for divine guidance. Audrey L. Kuhn invites readers to embrace their own narratives, reminding them that even in the darkest moments, they are never truly alone. Her journey serves as a source of comfort and inspiration, affirming the indomitable power of resilience, love, and faith. God's Voice Through the Despair is available for purchase online at and About the Author: Audrey L. Kuhn, a native of Lancaster County, Pennsylvania, is the fifth of seven children from a conservative, faith-rooted family. Her writings reflect her resilient character and compassionate spirit. Inspired by the beauty of creation, her poetry explores themes of life, death, and beyond. Many of her poems have been shared at church gatherings, funerals, and in collaborative works like Poems and Harp for the Soul. Known for her heartfelt verses, Audrey's work offers comfort to those experiencing grief or loss. Her book, God's Voice Through the Despair, showcases her enduring faith and spiritual insight. Media Contact: poemsbyaudrey@ Available for interviews: Author, Audrey L. Kuhn Attachment God's Voice Through the Despair CONTACT: Leah Joseph Palmetto Publishing publicity@
Yahoo
2 hours ago
- Yahoo
Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge
The Mexico Microcarrier Market is poised for significant growth, projected to reach US$ 77.65 million by 2033 from US$ 39.96 million in 2024, achieving a CAGR of 7.66% from 2025 to 2033. Key drivers include increased investment in regenerative medicine and cell therapy, rising demand for cell-based vaccines and biologics, and technological advancements in cell culture efficiency. Mexico's biopharmaceutical sector expansion, supported by enhanced bioprocessing infrastructure and strategic public-private partnerships, further bolsters this growth. Emerging challenges include high setup costs and complex regulatory requirements, offering opportunities for innovation and collaboration. Mexican Microcarrier Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Mexico Microcarrier Market to Reach US$ 77.65 Million by 2033 - 7.66% CAGR Growth Driven by Biopharma Demand" report has been added to Mexico Microcarrier Market is expected to reach US$ 77.65 million by 2033 from US$ 39.96 million in 2024, with a CAGR of 7.66% from 2025 to 2033. Growing investment in regenerative medicine and cell therapy, growing demand for cell-based vaccines and biologics, technological advancements in culture efficiency, and expansion of biopharmaceutical research and development in Mexico. Mexico's growing biopharmaceutical and biotechnology industries depend heavily on the microcarrier industry. The large-scale manufacturing of biologics, vaccines, and cell treatments depends on microcarriers, which are tiny, spherical particles that promote the proliferation of adherent cells in bioreactors. As Mexico looks to improve its local manufacturing capabilities in response to growing healthcare demands and the need for medical product self-sufficiency, these applications become more and more market is expanding due to a number of causes. Research and development expenditures, along with the nation's strategic efforts to strengthen its biomanufacturing infrastructure, are essential. The need for effective cell culture systems is further fueled by the aging population and the rising incidence of chronic diseases, which increase demand for cutting-edge treatment solutions. Additionally, Mexico has easier access to cutting-edge biotechnologies, such as microcarrier-based cell culture systems, thanks to its involvement in international health programs and collaborations with foreign the encouraging growth trajectory, the Mexican microcarrier market still confronts obstacles including the requirement for specialized technological know-how and the development of strong regulatory frameworks to guarantee the quality and safety of the products. Nonetheless, these difficulties offer chances for creativity and cooperation. These problems can be resolved by creating training initiatives, establishing regulatory guidelines, and encouraging public-private partnerships. This will create an atmosphere that is favorable for the expansion of the microcarrier market and the larger biopharmaceutical sector in Factors Driving the Mexico Microcarrier Market Growth Increasing Demand for Cell Therapy and BiopharmaceuticalsMicrocarrier systems are in high demand due to Mexico's growing biopharmaceutical industry, which includes the manufacture of vaccines, biologics, and cell treatments. Businesses are depending more and more on microcarriers to sustain high density adherent cell cultures in bioreactors as local R&D becomes more intense and manufacturing capacity need is particularly noticeable in the creation of therapeutic proteins, monoclonal antibodies, and items related to regenerative medicine. Scalable and effective cell culture is made possible by microcarriers, which is necessary for the commercial production of biologics and sophisticated cell culture systems are now a vital enabling technology for Mexico's biomanufacturing efforts as the nation develops its capacities in these fields and aligns with international health Development and Manufacturing ExpansionMexico's bioprocessing infrastructure is being quickly strengthened through government sponsored initiatives and strategic public-private partnerships. The adoption of effective cell culture technologies is being fueled by investments in upstream bioprocessing facilities, automation, single use systems, and digital technology is also supported by the growth of industry academia partnership and regulatory modernization (e.g., COFEPRIS's digital transformation). These advancements promote easier technology transfer from research to production and improve the technical preparedness required for microcarrier is therefore better able to scale complex bioprocesses, which increases the accessibility of microcarriers for biotechnology companies, contract manufacturers, and academic institutions seeking to increase their capacity for and Technological Progress in MicrocarriersPerformance and scalability have been greatly enhanced by innovations in microcarrier design, such as surface functionalized beads, biodegradable materials, and compatibility with single use bioreactors. Manufacturers who prioritize quality and cost effectiveness are placing a greater value on enhanced features like increased yield, better cell adhesion, and lower contamination developments, when combined with automation, intelligent sensor integration, and digital process control, reduce human error and streamline production. Modern microcarrier formats are becoming feasible choices for biomanufacturers and researchers nation wide due to Mexico's rising alignment with international industry trends and the country's expanding adoption of state of the art bioprocessing in the Mexico Microcarrier Market Expensive Startup and Ongoing CostsMicrocarrier based cell culture system deployment requires a large financial outlay, especially for equipment such as bioreactors, single use systems, and associated infrastructure. Traditional planar culture techniques are still less expensive at lower scales because they require less like microcarrier beads make up a significant portion of the continuous expenses for microcarrier setups, which frequently require tens or even hundreds of thousands of dollars in capital expenditure. GMP grade, high quality microcarriers can account for 20-25% of total consumable financial barriers, in addition to media supplies and labor training, make the technology hard to adopt in Mexico, where a large number of biotech companies and academic institutions have tight budgets. Despite the long term productivity and efficiency benefits of microcarriers, this hinders scale of Regulations and Documentation NeedsUnder the General Health Law, COFEPRIS is in charge of regulating microcarrier based cell culture in Mexico, particularly when it is meant for clinical or therapeutic applications. In accordance with ICH guidelines, businesses are required to compile comprehensive Common Technical Document (CTD) dossiers that include clinical, non clinical, and quality is necessary to adhere to Official Mexican Standards (such as NOM?257?SSA1?2014, NOM?059?SSA1?2015), especially those that deal with GMP, bio comparability, and safety assessment. Microcarrier systems need to be thoroughly validated, which includes testing for batch uniformity, sterility, and cell material obstacles to commercialization include the burden of complicated documentation and testing, changing regulations, and unclear advanced therapeutic standards. Market access may be delayed, more expensive, and unclear for entities without local regulatory partnerships or past dossier experience. Company Analysis: Overview, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis Thermo Fisher Scientific Merck KGaA Eppendorf AG Danaher Corporation Sartorius AG Bio Rad Laboratories, Inc. Corning Inc. Lonza Group Getinge Becton, Dickinson and Company Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $39.96 Million Forecasted Market Value (USD) by 2033 $77.65 Million Compound Annual Growth Rate 7.6% Regions Covered Mexico Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Mexico Microcarrier Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product Type6.2 By Application6.3 By End User6.4 By Region7. Product Type7.1 Consumables7.1.1 Microcarrier Beads7.1.2 Media & Reagents7.2 Equipment8. Application8.1 Cell Therapy8.1.1 Market Analysis8.1.2 Market Size & Forecast8.2 Vaccine Manufacturing8.3 Others9. End User9.1 Pharmaceutical & Biotechnology Companies9.2 Contract Research Organizations & Contract Manufacturing Organizations9.3 Academic & Research Institutes10. Region10.1 Northern Mexico10.2 Central Mexico10.3 Southern Mexico10.4 Others11. Value Chain Analysis12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Competition12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threats14. Pricing Benchmark Analysis14.1 Thermo Fisher Scientific14.2 Merck KGaA14.3 Eppendorf AG14.4 Danaher Corporation14.5 Sartorius AG14.6 Bio-Rad Laboratories, Inc.14.7 Corning Inc.14.8 Lonza Group14.9 Getinge14.10 Becton, Dickinson and Company15. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Mexican Microcarrier Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
